Roland Zahn, Ph.D., a Janssen scientist and expert in viral vaccines, was at the front lines of research during the Ebola outbreak. Today he and his team are working at record speed to help deliver a potential vaccine for the novel coronavirus.
Weeks before many people had even heard of the novel coronavirus, Roland Zahn, Ph.D., was already studying the disease—specifically, how it could be stopped.
OSD products show great promise as treatments for the symptoms of COVID-19.
The global pandemic and economic shutdown facing us today is unlike anything most of us have seen in our lifetime. Around the world, the threat of COVID-19 has forced everyday life to come to a standstill.
Essential strategies to position your ATMP facility for success.
It’s a thrilling time to be part of an advanced therapy medicinal product (ATMP) project. You’re working on a new frontier of scientific discovery, using some of the fastest-evolving and most complex techniques available to potentially cure our most malignant diseases. For patients and drug developers alike, ATMP manufacturing could be a dream come true.
Chairman & CEO Alex Gorsky shares that the company could have the first batches of a Covid-19 vaccine available for emergency-use authorization in early 2021—a substantially accelerated time frame in comparison to the typical vaccine development process.
By Alex Gorsky, Chairman & CEO,
The Covid-19 pandemic is one of the greatest challenges to our society in living memory.
Yet even as we are heartbroken by the lives lost and the strain on our institutions and communities, countless people have been working tirelessly to offer the world a reason to feel pride, inspiration and hope.
Hilton (NYSE:HLT) and American Express (NYSE:AXP) today announced that the companies, in partnership with Hilton’s ownership community, will donate up to 1 million hotel room nights across the United States to frontline medical professionals leading the fight against COVID-19.
Beginning next week, Hilton and American Express will make rooms available without charge to doctors, nurses, EMTs, paramedics and other frontline medical staff who need a place to sleep, recharge or isolate from their families through the end of May.
As SARS-CoV-2 moves fast through our global population, the pharmaceutical industry faces tremendous pressure to move even faster.
March, 2020 - /3BL Media/ - Industry leaders are jousting with questions of how to quickly evaluate new and repurposed drugs while simultaneously readying their operations for rapid transformation. Novel partnerships between private R&D teams and public health agencies are emerging to address the “discovery” half of that equation, which leaves company leaders to grapple with the other half: how can they prepare their operations for commercial-scale manufacturing of a therapy that hasn’t yet been identified or approved?